Ultragenyx Pharmaceutical RARE D&A

D&A at other companies

Eli LillyLLY

$534M+11.7%

AmgenAMGN

$1.11B-17.1%

Ionis PharmaceuticalsIONS

$3.43M+51.5%

Arrowhead ResearchARWR

$6.37M+4.7%

Zevra Therapeutics, Inc.ZVRA

$364K-78.0%

RegenxbioRGNX

$3.76M-3.8%

FAQ

What is Ultragenyx Pharmaceutical's D&A?

Ultragenyx Pharmaceutical (RARE) reported D&A of $8M in Q2 2026.

How has Ultragenyx Pharmaceutical's D&A changed year-over-year?

Ultragenyx Pharmaceutical's D&A decreased by 11.1% year-over-year, from $9M to $8M.

What is the long-term trend for Ultragenyx Pharmaceutical's D&A?

Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's D&A has grown at a 27.5% compound annual growth rate (CAGR), from $13.24M to $35M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.